IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Carcy et al.

Serial No.: 10/563,601 (National Phase entry under 35 U.S.C. § 371 of

PCT/EP2004/051454, filed July 12, 2004)

Confirmation No.: 8856

§ 371 File Date: May 4, 2006

Group Art Unit: 1645

Examiner: Archie, N.

For: Babesia Vaccines

Attorney Docket: I-2003.005 US

December 6, 2007

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313

Sir/Madam:

In reply to the Restriction Requirement mailed November 16, 2007, Applicants elect Group I without traverse, and the species *Babesia canis*. Although this species is not included in the Examiner's species list, it is abundantly clear from Applicants' specification that this is the species from which the sequence Bc28.1 was originally derived (hence the B.c. abbreviation in the protein's name). Also the description is full of references to this as the preferred species; see for instance in the application as published by the PCT (WO 2005/012343): the figure on the front page; page 4 lines 1-3; page 5 lines 11 - 24; page 8, line 29 - page 9, line 3; page 9, lines 22-23; etc. Claims 1, 2, 4-5, 7-15 and 19-21 read on the elected invention.

USSN 10/563,601 Attorney Docket: 2003.005 US Response to Restriction Requirement

Applicants do not believe that any other fee is due in connection with this filing. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. 02-2334. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or 1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. 02-2334.

Respectfully Subm

Aaron L. Schwartz

PTO Reg. No. 48,181

Intervet Inc.
Patent Department
P.O. Box 318
29160 Intervet Lane
Millsboro, DE 19966
(302) 933-4034 (tel)
(302) 934-4305 (fax)